اَخر الأخبار
Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25
Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, 2025. Despite a significant drop in net profit, revenue and EBITDA have grown. Increased biosimilar market share and strategic approvals are expected to drive future growth.
For more details: Click here